Please login to the form below

Not currently logged in
Email:
Password:

Orexigen

This page shows the latest Orexigen news and features for those working in and with pharma, biotech and healthcare.

Takeda files block on generic diet pill launch

Takeda files block on generic diet pill launch

Orexigen and its partner Takeda have taken Actavis to court to block a generic version of the firms' diet pill Contrave. ... The lawsuit alleges that the generic drugmaker Actavis has infringed patents on Orexigen and Takeda's new weight-loss treatment

Latest news

  • Saxenda debuts in US with $1,000-a-month price tag Saxenda debuts in US with $1,000-a-month price tag

    The Danish drugmaker has launched Saxenda in the US at a price of just over $1, 000 per month, significantly more than other recently-launched obesity drugs such as

  • Positive data in Saxenda diabetes prevention study Positive data in Saxenda diabetes prevention study

    the US of three other drugs; Eisai and Arena's Belviq (lorcaserin), Vivus' Qsymia (phentermine/topiramate) and Orexigen's Contrave (naltrexone and bupropion). ... None of these has made significant headway since their US launches, and of the three only

  • CHMP thumbs up for Novo's obesity drug Saxenda CHMP thumbs up for Novo's obesity drug Saxenda

    new products - Eisai and Arena's Belviq (lorcaserin), Vivus' Qsymia (phentermine/topiramate) and Orexigen's Contrave (naltrexone and bupropion) in the last couple of years in the US and other world ... markets. The picture in Europe is different, however,

  • FDA approval for Novo Nordisk's obesity shot FDA approval for Novo Nordisk's obesity shot

    1999. In the last two years three other drugs have gained US marketing approval, including: Orexigen's Contrave, Vivus' Qsymia (phentermine/topiramate) and Arena Pharmaceuticals' Belviq (lorcaserin).

  • Orexigen’s obesity pill Mysimba set for European approval Orexigen’s obesity pill Mysimba set for European approval

    Orexigen’ s obesity pill Mysimba set for European approval. But sales of the treatment are only predicted to reach $200m by 2016. ... The drug is a combination of the antidepressant bupropion and Orexigen's formulation of naltrexone, a drug designed to

More from news
Approximately 4 fully matching, plus 19 partially matching documents found.

Latest appointments

  • Mark Booth joins Probiodrug Mark Booth joins Probiodrug

    Booth joins the Alzheimer's disease specialty biopharmaceutical firm from Orexigen Therapeutics, where he served as chief commercial officer leading its business development and investor relations activities.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Star

We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...

Latest intelligence

Shanghai
Biopharma's Future: Made in China
The world’s second biggest pharma market is entering a new growth phase – but meeting its needs takes investment and expertise...
Solaris Health looks at the gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....

Infographics